Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
about
Tubulin-interactive natural products as anticancer agentsScrutinizing the scaffolds of marine biosynthetics from different source organisms: Gram-negative cultured bacterial products enter center stageStabilized Polymer Micelles for the Development of IT-147, an Epothilone D Drug-Loaded FormulationProfile and potential of ixabepilone in the treatment of pancreatic cancerRandomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneBeyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.Novel microtubule-targeting agents - the epothilones.Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.Violacein induces p44/42 mitogen-activated protein kinase-mediated solid tumor cell death and inhibits tumor cell migrationEpothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsStrategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.Lapatinib and ixabepilone for the treatment of metastatic breast cancer.Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancerMicrotubule dynamics as a target in oncology.The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.Ixabepilone: a new active chemotherapy in the treatment of breast cancer.Management of advanced breast cancer with the epothilone B analog, ixabepiloneMicrotubule stabilising agents for cancer chemotherapy.Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.From bench to bedside: the growing use of translational research in cancer medicine.Microbial-based therapy of cancer: current progress and future prospects.Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.Ixabepilone for the treatment of endometrial cancer.Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy.Multiple Effects of a Novel Epothilone Analog on Cellular Processes and Signaling Pathways Regulated by Rac1 GTPase in the Human Breast Cancer CellsRadiosensitizing effect of epothilone B on human epithelial cancer cells.Metronomic dosing enhances the anti-angiogenic effect of epothilone B.Exposure-response relationship of the synthetic epothilone sagopilone in a peripheral neurotoxicity rat model.Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
P2860
Q24650163-087E377B-CB90-4688-A715-8E8914F2373AQ26860194-0192A233-1912-4890-A7E7-DAEA02EA7FC5Q28817437-1150B2BE-1F09-4197-9136-FCB56C64F1EEQ33933685-4870B18A-BFA3-4FBA-B999-01895980A34AQ33990883-CF52D7F6-59AD-4009-8044-977FA5120830Q33999018-EFC22624-7923-440B-82F5-3644BD3950C4Q34611212-F4EA6816-BED0-4ABB-87A6-5C1224B5B64FQ35623301-EDE15F35-5F75-4F75-9A62-E2F609B9217EQ35628391-02E82B74-F24D-403D-8A62-F0677C60B626Q35997562-7F37E385-3616-4BE5-A9A0-BC47E73B6255Q36273796-8230D5C9-96F2-4292-B19D-675B95F6EDA3Q36372894-5BBE74CA-0ACA-4CD8-8547-4E483DFF8305Q37169723-2A1CC7FC-863D-4F95-8DC6-B855ACD9E45BQ37236419-892D690B-D1BC-4139-ACC1-3E61D40B78AFQ37281586-5E333947-3671-4AF9-B468-5778FBEDFE60Q37290709-13EC2789-7705-4FDF-BEDF-AF2C3941C03AQ37360708-DB7C9AE4-5BE3-4F4C-B118-AF046209F27FQ37378233-BF6F741F-863A-481F-9B46-38B87E6B9C40Q37398150-CFA14DD0-43FD-4225-930B-65463C2360BFQ37401833-9733D50B-5B64-460F-8FE4-D5903C643BC5Q37403186-8552D598-09C3-45CF-8AFE-3DE76252AC05Q37481355-EAE30BD6-6384-42E0-8077-E6851F8F5ADCQ37481367-6D5475C0-0460-4AA2-9E01-71510E367374Q37698244-2F46F8A3-FB0B-416C-9F06-A96C6B07154AQ37843621-1E66BFF7-6EE6-4825-B49B-BD8A1F4A4236Q38224422-E20DF9E3-1D33-4233-A3DC-69181D395BBBQ38763500-C389540C-79C4-4652-AC82-5B93069CE9EEQ38789551-F11295FE-B28E-49EA-9D88-FDC458FE20A2Q38869231-4670EF3D-733C-4961-A26A-04464F1CA8EFQ39414221-A0E18F8C-E4E5-4AE5-9BA3-6E01C47585BDQ42563683-AF6D2EBC-00F7-4871-A3E5-1F4EE11153CCQ43702348-27CFDE8E-BA80-44A6-8118-1D9DDA701D01Q54685246-6CE1C43E-2573-4FF0-94CD-0FAFBE7AF9D2
P2860
Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Novel tubulin-targeting agents ...... hilones and related analogues.
@en
type
label
Novel tubulin-targeting agents ...... hilones and related analogues.
@en
prefLabel
Novel tubulin-targeting agents ...... hilones and related analogues.
@en
P2093
P356
P1433
P1476
Novel tubulin-targeting agents ...... hilones and related analogues.
@en
P2093
P356
10.1093/ANNONC/MDM173
P478
18 Suppl 5
P577
2007-07-01T00:00:00Z